Piramal Pharma to invest USD 90M in expansion of two US sites
Mumbai: Piramal Pharma Limited, a global pharmaceuticals and wellness company, in conjunction with the 2025 Select USA Investment Summit, has committed to a $90M investment plan towards expanding two of the Company’s US facilities.
These expansions are in response to ongoing demand from US customers, in support of the trend towards US onshoring of drug supply. Piramal Pharma is making brownfield expansions to existing sites, financed by bank loans and internal accruals, which is the fastest, lowest risk, and most economical way to add new capacities to the US market.
Piramal Pharma’s Lexington, Kentucky, facility specializes in sterile compounding, liquid filling, and lyophilization for sterile injectable drug products. The site’s expansion—which includes 24,000 square feet of manufacturing space and a new laboratory—adds commercial-scale manufacturing. Key additions include a new filling line, two commercial-size lyophilizers, a special capping machine, and an external vial washer. The facility is expected to be completed and online by late 2027.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.